Paper20173017
Long-term use of bisphosphonates in osteoporosis.
Watts NB and 1 other. J Clin Endocrinol Metab, 2010. Cited by 388 papers, by iCite.
Cite this record
ConductScience Library. Long-term use of bisphosphonates in osteoporosis. Papers, record 20173017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20173017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Density Conservation Agents | Major topic |
| Diphosphonates | Major topic |
| Osteoporosis | Major topic |
| Atrial Fibrillation | |
| Clinical Trials as Topic | |
| Esophageal Neoplasms | |
| Fractures, Bone | |
| Humans | |
| Jaw Diseases | |
| Kidney Diseases | |
| Long-Term Care | |
| Osteonecrosis | |
| Pain |
Source PubMed
Cited by194
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 388 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42395110 | Incidental Unilateral Lateral Cortical Hypertrophy of the Proximal Femur Following Low-Energy Trauma Without Prior Bisphosphonate Exposure: A Case Report. | Case Rep Orthop | 2026 | https://conductscience.org/library/papers/42395110 | PubMed |
| 42216162 | Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross‑sectional study. | BMC Oral Health | 2026 | https://conductscience.org/library/papers/42216162 | PubMed |
| 41886884 | Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis. | Breast | 2026 | https://conductscience.org/library/papers/41886884 | PubMed |
| 41754798 | Probing the Hydrophobic Part of Analogues of the Incadronate-Evidence of Their Interaction with Immunological System of Sheep. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754798 | PubMed |
| 41701231 | Clarifying clinically treatment-naive status for osteoporosis patients. | Osteoporos Int | 2026 | https://conductscience.org/library/papers/41701231 | PubMed |
| 41583080 | Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study. | Atheroscler Plus | 2026 | https://conductscience.org/library/papers/41583080 | PubMed |
| 41565170 | Improvements in bone quality by parathyroid hormone treatment are enhanced in the Nmp4 knockout mouse model. | Bone | 2026 | https://conductscience.org/library/papers/41565170 | PubMed |
| 41466542 | Medication-related osteonecrosis of the jaw: an evidence-based 2025 position statement from a Korean multidisciplinary task force. | J Korean Assoc Oral Maxillofac Surg | 2025 | https://conductscience.org/library/papers/41466542 | PubMed |
| 41444308 | Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation. | Sci Rep | 2025 | https://conductscience.org/library/papers/41444308 | PubMed |
| 41391453 | Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force. | Endocrinol Metab (Seoul) | 2025 | https://conductscience.org/library/papers/41391453 | PubMed |
| 41303575 | Modern Strategies for Osteoporosis Therapy: Current Status and Prospects for Targeted Intervention. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303575 | PubMed |
| 41252551 | Antiosteolytic Bisphosphonate Metallodrug Coordination Networks: Dissolution Profiles and In Vitro/In Vivo Toxicity toward Controlled Release. | ACS Appl Bio Mater | 2025 | https://conductscience.org/library/papers/41252551 | PubMed |
| 41132665 | Macrophages and osteoclasts: similarity and divergence between bone phagocytes. | Front Immunol | 2025 | https://conductscience.org/library/papers/41132665 | PubMed |
| 41113720 | 99Tc-MDP maintains bone mineral density for postmenopausal differentiated thyroid cancer patients with osteopenia under thyroid-stimulating hormone suppression. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41113720 | PubMed |
| 40952460 | [Antiresorptive therapies in osteoporosis]. | Orthopadie (Heidelb) | 2025 | https://conductscience.org/library/papers/40952460 | PubMed |
| 40557948 | How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy? | Acta Oncol | 2025 | https://conductscience.org/library/papers/40557948 | PubMed |
| 40404831 | Adaptation of mitochondrial bioenergetics to coenzyme Q deficiency in human endothelial cells after chronic exposure to bisphosphonates. | Sci Rep | 2025 | https://conductscience.org/library/papers/40404831 | PubMed |
| 40353205 | Osteogenesis imperfecta: exploring an autoimmune and immunotherapy perspective. | JBMR Plus | 2025 | https://conductscience.org/library/papers/40353205 | PubMed |
| 40224033 | Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy. | J Dent Sci | 2025 | https://conductscience.org/library/papers/40224033 | PubMed |
| 40219574 | [Bisphosphonates-related osteonecrosis of the jaw: A case report]. | Beijing Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/40219574 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20173017
GET https://conductscience.org/api/papers/v1/20173017/cited_by?page=2